Chronic Spontaneous Urticaria Following Pfizer-BioNTech Coronavirus Disease 2019 Messenger RNA Vaccination

Michael J. Adame; Nicole A. Christians; Aisha Q. Mohammed; Julia W. Tripple

doi:10.7326/aimcc.2021.0055

Chronic Spontaneous Urticaria Following Pfizer-BioNTech Coronavirus Disease 2019 Messenger RNA Vaccination

Michael J. Adame, Nicole A. Christians, Aisha Q. Mohammed, Julia W. Tripple

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Since the introduction of coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines, much attention has been paid to adverse reactions. Numerous cutaneous reactions are described in the literature, but less so about chronic spontaneous urticaria (CSU). CSU is described as recurrent hives with no identifiable trigger, with or without angioedema, which persists for more than 6 weeks. It can be a frustrating diagnosis for physicians and patients alike because of the difficulty in identification and management. The mainstay of CSU treatment is antihistaminergic therapy. In this case, we describe a 35-year-old woman who was newly diagnosed with CSU after receiving the Pfizer-BioNTech COVID-19 mRNA vaccine.

Original language	English (US)
Article number	e210055
Journal	Annals of Internal Medicine Clinical Cases
Volume	1
Issue number	4
DOIs	https://doi.org/10.7326/aimcc.2021.0055
State	Published - Jun 2022
Externally published	Yes

Keywords

Adverse reactions
COVID-19
Urticaria
Vaccines

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Internal Medicine
Clinical Biochemistry

Access to Document

10.7326/aimcc.2021.0055

Cite this

@article{071e0ba8467445bdbdb3da0a898405ee,

title = "Chronic Spontaneous Urticaria Following Pfizer-BioNTech Coronavirus Disease 2019 Messenger RNA Vaccination",

abstract = "Since the introduction of coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines, much attention has been paid to adverse reactions. Numerous cutaneous reactions are described in the literature, but less so about chronic spontaneous urticaria (CSU). CSU is described as recurrent hives with no identifiable trigger, with or without angioedema, which persists for more than 6 weeks. It can be a frustrating diagnosis for physicians and patients alike because of the difficulty in identification and management. The mainstay of CSU treatment is antihistaminergic therapy. In this case, we describe a 35-year-old woman who was newly diagnosed with CSU after receiving the Pfizer-BioNTech COVID-19 mRNA vaccine.",

keywords = "Adverse reactions, COVID-19, Urticaria, Vaccines",

author = "Adame, {Michael J.} and Christians, {Nicole A.} and Mohammed, {Aisha Q.} and Tripple, {Julia W.}",

note = "Publisher Copyright: {\textcopyright} 2022 Authors.",

year = "2022",

month = jun,

doi = "10.7326/aimcc.2021.0055",

language = "English (US)",

volume = "1",

journal = "Annals of Internal Medicine Clinical Cases",

issn = "2767-7664",

publisher = "American College of Physicians",

number = "4",

}

TY - JOUR

T1 - Chronic Spontaneous Urticaria Following Pfizer-BioNTech Coronavirus Disease 2019 Messenger RNA Vaccination

AU - Adame, Michael J.

AU - Christians, Nicole A.

AU - Mohammed, Aisha Q.

AU - Tripple, Julia W.

PY - 2022/6

Y1 - 2022/6

N2 - Since the introduction of coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines, much attention has been paid to adverse reactions. Numerous cutaneous reactions are described in the literature, but less so about chronic spontaneous urticaria (CSU). CSU is described as recurrent hives with no identifiable trigger, with or without angioedema, which persists for more than 6 weeks. It can be a frustrating diagnosis for physicians and patients alike because of the difficulty in identification and management. The mainstay of CSU treatment is antihistaminergic therapy. In this case, we describe a 35-year-old woman who was newly diagnosed with CSU after receiving the Pfizer-BioNTech COVID-19 mRNA vaccine.

AB - Since the introduction of coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines, much attention has been paid to adverse reactions. Numerous cutaneous reactions are described in the literature, but less so about chronic spontaneous urticaria (CSU). CSU is described as recurrent hives with no identifiable trigger, with or without angioedema, which persists for more than 6 weeks. It can be a frustrating diagnosis for physicians and patients alike because of the difficulty in identification and management. The mainstay of CSU treatment is antihistaminergic therapy. In this case, we describe a 35-year-old woman who was newly diagnosed with CSU after receiving the Pfizer-BioNTech COVID-19 mRNA vaccine.

KW - Adverse reactions

KW - COVID-19

KW - Urticaria

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85168836041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85168836041&partnerID=8YFLogxK

U2 - 10.7326/aimcc.2021.0055

DO - 10.7326/aimcc.2021.0055

M3 - Article

AN - SCOPUS:85168836041

SN - 2767-7664

VL - 1

JO - Annals of Internal Medicine Clinical Cases

JF - Annals of Internal Medicine Clinical Cases

IS - 4

M1 - e210055

ER -

Chronic Spontaneous Urticaria Following Pfizer-BioNTech Coronavirus Disease 2019 Messenger RNA Vaccination

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this